Nocebo effects with antidepressant clinical drug trial placebos

General Hospital Psychiatry

Volumn 29, Issue 3, 2007, Pages 275-277

  Reeves, Roy R ^a,b   Ladner, Mark E ^a,b   Hart, Roy H ^a   Burke, Randy S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Nocebo; Placebo

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; INFUSION FLUID; NOCEBO; PLACEBO; SERTRALINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD EXAMINATION; BLOOD PRESSURE MONITORING; CASE REPORT; DEPENDENT PERSONALITY DISORDER; DEPRESSION; DRUG OVERDOSE; HEART RATE; HUMAN; HYPOTENSION; MALE; PARESTHESIA; PHYSICAL EXAMINATION; PSYCHOTHERAPY; SEDATION;

ADULT; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS; HYPOTENSION; MALE; PERSONALITY TESTS; PLACEBO EFFECT; PLACEBOS; TREATMENT OUTCOME;

EID: 34247627983     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2007.01.010     Document Type: Article

References (18)

1. Benson H. The nocebo effect: history and physiology. Prev Med 26 (1997) 612-615
2. Hahn R.A. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 26 (1997) 607-611
3. Flaten M.A., Simonsen T., and Olsen H. Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosom Med 61 (1999) 250-255
4. Luperillo T.J., Leist N., Lourie C.H., and Sweet P. The interaction of psychologic stimuli and pharmacologic agents on airway reactivity. Psychosom Med 32 (1970) 509-513
5. Jewett D.L., Fein G., and Greenburg M.H. A double-blind study of symptom provocation to determine food sensitivity. N Engl J Med 323 (1990) 429-433
6. Zubieta J., Bueller J.A., Jackson L.R., et al. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J Neurosci 25 (2005) 7754-7762
7. Johansen O., Brox J., and Flaten M.A. Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosom Med 65 (2003) 786-790
8. de la Fuente-Fernandez R., Ruth T.J., Sossi V., et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 (2001) 1164-1166
9. Ader R. Conditioned immunomodulation: research needs and directions. Brain Behav Immun 17 (2003) S51-S57
10. Wager T.D., Rilling J.K., Smith E.E., et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 303 (2004) 1162-1167
11. Mayberg H.S., Silva J.A., Brannan S.K., et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 159 (2002) 728-737
12. Leuchter A.F., Cook I.A., Witte E.A., et al. Changes in brain function of depressed patients during treatment with placebo. Am J Psychiatry 159 (2002) 122-129
13. Hunter A.M., Leuchter A.F., Morgan M.L., and Cook I.A. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry 163 (2006) 1426-1432
14. Barsky A.J., Saintford R., Rogers M.P., and Borus J.F. Nonspecific medication side effects and the nocebo phenomenon. JAMA 287 (2002) 622-627
15. Brown W.A. Placebo as a treatment for depression. Neuropsychopharmacology 10 (1994) 265-269
16. Khan A., Warner H.A., and Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry 57 (2000) 311-317
17. Kirsch I., and Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and treatment (1998). http://journals@apa.org/prevention/volume1/pre0010002a.html Article 0002a. http://journals@apa.org/prevention/volume1/pre0010002a.html
18. Loebel A.D., Hyde T.S., and Dunner D.L. Early placebo response in anxious and depressed patients. J Clin Psychiatry 47 (1986) 230-233